OR WAIT null SECS
The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.
August 09, 2024
Article
Findings from a prespecified secondary analysis of the reduced-dose cohort of the TESTING trial suggest the efficacy of a lower dose of oral methylprednisolone in IgA nephropathy.
August 08, 2024
On August 07, 2024, Novartis announced the FDA's accelerated approval of iptacopan for reducing proteinuria in primary IgAN based on interim data from APPLAUSE-IgAN.
August 07, 2024
Study findings suggest the need for individualized management of patients with IgAN following COVID-19 infection based on baseline renal function status.
August 02, 2024
Findings support the use of mineralocorticoid receptor antagonists for the short-term reduction of proteinuria in patients with IgAN.
This July 2024 month in review highlights renal pipeline updates, new patient-focused CKD guidelines, and other top nephrology news and research.
July 15, 2024
The high diagnostic and prognostic application values of newer IgAN machine learning models suggest their eventual utility in clinical practice.
July 11, 2024
Findings suggest greater CTSS levels are associated with an elevated risk of IgAN and highlight the enzyme’s potential as a diagnostic biomarker.
July 09, 2024
Gross hematuria due to infection was not associated with the incidence of gross hematuria due to vaccination in patients with IgAN who received COVID-19 mRNA vaccination.
July 05, 2024
Patients with chronic tonsillitis had greater IgAN event rates than those without, and further analysis revealed chronic tonsillitis was linked to a greater risk of developing IgAN.
July 02, 2024
Findings highlight the prognostic value of metabolic syndrome components in predicting both renal and cardiovascular outcomes in patients with IgA nephropathy.